Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

High-grade disease was associated with worse survival outcomes in Black patients with uterine carcinoma.

High-Grade Cancer, But Not SVM, Is Associated With OS Disparities in Black Patients With Uterine Carcinoma

R. Tyler Hillman, MD, PhD, discusses ways of identifying new drug therapy candidates in patients with adult-type granulosa cell tumor of the ovary. 

Dr Hillman on Identifying New Therapy Candidates in Adult-Type Granulosa Cell Tumor

Angeles Alvarez Secord, MD, MHSc, discusses findings from the consensus report published by the National Academies of Sciences, Engineering, and Medicine committee. 

Dr Secord on the National Academies of Sciences, Engineering, and Medicine’s Assessment of Women’s Health Research at the NIH

The addition of chemotherapy to radiation therapy following surgery conferred a benefit in certain endometrial cancer molecular subtypes.

Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

An observational cohort study determined that discordance exists between p53 protein expression and TP53 mutation status in high-risk endometrial cancer. 

Observational Data Challenge p53 Expression as a Surrogate Marker for TP53 Mutations in High-Risk Endometrial Cancer

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

In case you missed any, read a recap of the episodes of OncLive On Air that aired in January 2025. 

Revisit Every OncLive On Air Episode From January 2025

The podcast section includes OncLive on Air® podcast episodes, which focus on clinical oncology news and expert insights in cancer care. Listen on OncLive.

Podcasts | Clinical Oncology News & Insights | OncLive

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

CME Opportunities

Specialty

, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

 covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Saurabh Dahiya, MD, FACP, and Shyam A. Patel, MD, PhD, about their research into the risk of developing second primary cancers (SPCs) following CAR T-cell therapy and how this risk, though low, may be mitigated. Dr Dahiya is an associate professor of medicine at Stanford University School of Medicine and Clinical Director of Cancer Cell Therapy in the Stanford BMT and Cell Therapy division in Palo Alto, California. Dr Patel is an associate professor in the Department of Medicine at the UMass Chan Medical School, as well as a hematologist/oncologist at UMass Memorial Medical Center in Worcester, Massachusetts.

In our exclusive interview, Drs Dahiya and Patel discussed the pathobiology of SPCs that develop after CAR T-cell therapy, potential SPC prevention strategies, and how SPC research may help optimize CAR T-cell product development in the future.

That’s all we have for today! Thank you for listening to this episode of 

. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit 

 is also on social media. On X, and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Drs Dahiya and Patel discuss how SPC research may help optimize CAR T-cell product development in the future.

How Second Primary Cancer Risk Factors Into CAR T-Cell Therapy Considerations: With Saurabh Dahiya, MD, FACP; and Shyam A. Patel, MD, PhD

, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life’s experiences.

In this episode, Dr Camidge is rejoined by Rahul Gosain, MD, MBA, the medical director of Wilmot Cancer Institute at Webster and director of Wilmot Cancer Institute Regional Infusion services, as well as an assistant professor of clinical medicine in the Department of Medicine, Hematology/Oncology at the University of Rochester in New York. Dr Gosain is also co-host of the podcast 

Drs Camidge and Gosain discuss what a typical day looks like in Dr Gosain's oncology practice; the importance of working closely with experts from other disciplines, including nurse practitioners; the challenges of maintaining work-life balance and preventing burnout; and the importance of oncology generalists in meeting the high demand for medical oncologists.

How Generalists Are Uniquely Positioned to Administer and Advance Oncology Care: With D. Ross Camidge, MD, PhD; and Rahul Gosain, MD, MBA

Thanks for your interest in this podcast. Please read this important program information before listening.

This PER® Spectives™ podcast episode features an interactive discussion on the evolving strategies in SCLC care. Key topics include the application of innovative therapeutic approaches, such as ADCs, bispecific antibodies, and novel treatments targeting DLL-3. This dynamic format explores ongoing challenges in SCLC management and discusses future clinical directions aimed at improving patient outcomes in real-world settings.

This activity is supported by an educational grant from Amgen.

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 

 Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

You may immediately download your certificate.

Associate Professor Section of Medical Oncology
Yale School of Medicine
Associate Cancer Center Director, Clinical Initiatives
Yale Cancer Center
New Haven, CT

 AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb; 

: Amgen, AstraZeneca, Daiichi Sankyo, Genentech, Janssen

Division Chief, Hematology/Oncology
University of Texas at Tyler School of Medicine
Tyler, TX

: AbbVie, AstraZeneca, Bristol Myers Squibb, Genentech, Johnson & Johnson, Sanofi.

Assistant Professor of Medicine, Harvard Medical School
Massachusetts General Hospital
Boston, MA

: AbbVie, AstraZeneca, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Janssen, Novartis, Spectrum Pharma, Takeda, Tesaro/GSK; 

: AstraZeneca, Bayer, Black Diamond Therapeutics, Boehringer Ingelheim, Eli Lilly, Genentech, Janssen, Merck, Sanofi, Taiho Pharma, Takeda; 

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Oncology PER® Spectives™: Transforming Treatment in Small Cell Lung Cancer: How Recent Trials Are Shaping Treatment Decision Making and Future Therapies

In today’s episode, we had the pleasure of speaking with David Gerber, MD, a professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center, a member of its Division of Hematology/Oncology, and co-director of Education and Training for the Harold C. Simmons Comprehensive Cancer Center in Dallas.

In our exclusive interview, Dr Gerber discussed the evolving role of antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC), focusing on findings from key clinical trials. He highlighted results from the phase 3 TROPION-Lung01 trial (NCT04656652), which demonstrated a modest improvement in progression-free survival with datopotamab deruxtecan-dlnk (Datroway), a TROP2-directed ADC, compared with docetaxel in patients with previously treated advanced NSCLC. He also emphasized the toxicity profile of TROP2-directed ADCs, particularly gastrointestinal toxicities and myelosuppression.

Dr Gerber also reviewed the phase 2 HERTHENA-Lung01 trial (NCT04619004) evaluating patritumab deruxtecan in patients with 

-mutant NSCLC and the phase 2 DESTINY-Lung02 trial (NCT04644237) assessing fam-trastuzumab deruxtecan-nxki (Enhertu) in those with 

-mutant NSCLC. Dr Gerber reflected on the shared DXd payload of these ADCs, highlighting its implications for toxicity and efficacy, as well as open questions regarding treatment sequencing and resistance mechanisms.

, supported by Amgen. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

Dr Gerber discusses the evolving role of ADCs in NSCLC, focusing on findings from clinical trials and considerations regarding the toxicity profile of TROP2-directed ADCs.

How are Antibody-Drug Conjugates Shaping the NSCLC Treatment Paradigm? With David Gerber, MD

In today’s episode, supported by Amgen, we had the pleasure of speaking with Ryan Cassaday, MD, an associate professor in the Clinical Research Division at the Fred Hutchinson Cancer Center and an associate professor in the Division of Hematology and Oncology at the University of Washington School of Medicine in Seattle, Washington. 

In our exclusive interview, Dr Cassaday discussed insights from several trials investigating blinatumomab (Blincyto) in patients with B-cell acute lymphoblastic leukemia (B-ALL) that were reported at the 2024 ASH Annual Meeting, including subgroup analyses of the phase 3 ECOG-ACRIN E1910 trial (NCT02003222). He also shared how findings from the phase 3 AALL1731 trial (NCT03914625) of blinatumomab plus chemotherapy in children with newly diagnosed B-ALL may be extrapolated to the adult B-ALL patient population. 

Ryan Cassaday, MD, discussed insights from trials investigating blinatumomab in patients with B-ALL that were reported at the 2024 ASH Annual Meeting.

Blinatumomab-Based Regimens Enhance and Refine the B-ALL Treatment Paradigm: With Ryan Cassaday, MD

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life’s experiences.

In this episode, Dr Camidge sits down with Adrienne A. Boire, MD, PhD, a neurologist, neuro-oncologist, and the Geoffrey Beene Junior Faculty Chair at Memorial Sloan Kettering Cancer Center in New York, New York.

Drs Camidge and Boire discuss Dr Boire's journey to becoming a physician-scientist, moments in her career that shaped her fascination with neurology, and how studying human biology at the cellular level can ultimately help improve the lives of patients with cancer.

Drs Camidge and Boire discuss Dr Boire's path to becoming a physician-scientist and how cellular biology research can improve outcomes for patients with cancer.

A Nuanced Understanding of Cellular Biology Advances Neuro-Oncology Practice: With D. Ross Camidge, MD, PhD; and Adrienne A. Boire, MD, PhD

In this Oncology PER® Spectives™ podcast episode, join 3 leading experts in oncology as they explore innovative approaches to treating ALK+ metastatic non-small cell lung cancer (mNSCLC). This engaging discussion focuses on molecular testing as the foundation of personalized therapy, the latest evidence on first-line therapies, and the vital role of multidisciplinary care for enhancing patient outcomes. Topics include selecting from available targeted therapies, overcoming barriers to comprehensive molecular diagnostics, and managing treatment-related adverse events. Tune in to gain actionable insights that will empower healthcare professionals to deliver optimized, guideline-driven care to patients with ALK+ mNSCLC.

This activity is supported by an educational grant from Takeda Pharmaceuticals USA, Inc.

William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

 AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Merck.

Associate Professor of Medicine
Harvard Medical School
Program Director, Center for Thoracic Cancers
Director, Targeted Immunotherapy
Massachusetts General Hospital
Boston, MA

Grant/Research Support Paid to Institution:

 Adaptimmune, Alexo, Array BioPharma, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Jounce Therapeutics, Merck, Moderna, Novartis, Palleon Pharmaceuticals, Tesaro; 

: Bristol Myers Squibb, Genentech/Roche Group, Gilead Sciences, iTeos Therapeutics, Jounce Therapeutics, Karyopharm Therapeutics, Loxo Oncology/Lilly, Mariana Oncology, Merck, Merus, Mirati Therapeutics, Moderna, Novartis, Novocure, Nuvalent, Pfizer, Silverback Therapeutics, Takeda.

Thoracic Medical Oncologist
Assistant Attending Physician
Memorial Sloan Kettering Cancer Center
Montvale, NJ

 AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, GI Therapeutics, Pfizer, Regeneron, Takeda.

Thoracic Medical Oncologist and Early Drug Development Specialist
Associate Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY

: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Cullinan, Daiichi Sankyo, Ipsen, Janssen, Takeda; 

Cases & Conversations: Integrating Novel Approaches to Treatment in First-Line ALK+ mNSCLC Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

In today’s episode, supported by Bristol Myers Squibb, we had the pleasure of speaking with Roxana S. Dronca, MD, about the FDA approval of subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig; subcutaneous nivolumab) for advanced or metastatic solid tumors. Dr Dronca is a professor of oncology, a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, and director of the Mayo Clinic Comprehensive Cancer Center in Jacksonville, Florida.

 across approved adult, solid tumor nivolumab indications, including as monotherapy, monotherapy maintenance after completion of nivolumab in combination with ipilimumab (Yervoy), or in combination with cabozantinib (Cabometyx) or chemotherapy. This regulatory decision was backed by findings from the phase 3 CheckMate-67T trial (NCT04810078) and includes indications for melanoma, renal cell carcinoma, non–small cell lung cancer, urothelial carcinoma, head and neck squamous cell carcinoma, colorectal cancer, esophageal carcinoma, esophageal adenocarcinoma, hepatocellular carcinoma, gastric cancer, and gastroesophageal junction cancer.

In our exclusive interview, Dr Dronca discussed the significance of this FDA approval across multiple solid tumor indications, pivotal findings from the CheckMate-67T trial, and how this approval represents a paradigm shift in modern cancer care delivery.

, supported by Bristol Myers Squibb. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

Dr Dronca discusses the FDA approval of subcutaneous nivolumab and hyaluronidase for advanced or metastatic solid tumors. 

FDA Approval Insights: Subcutaneous Nivolumab for Advanced Solid Tumors: With Roxana S. Dronca, MD

This PER® Spectives™ podcast episode, leading experts in acute myeloid leukemia (AML) discuss personalized management strategies for therapy-related AML and AML with IDH1 mutations, NPM1 mutations, and KMT2A rearrangements. Through engaging case studies and expert commentary, the panel delves into molecular testing, current and emerging therapies, and the role of innovative treatments like menin inhibitors. Designed for healthcare professionals, this episode provides actionable insights to guide treatment decisions and improve outcomes for special patient populations. Tune in to stay at the forefront of AML care.

This activity is supported by an educational grant from Rigel Pharmaceuticals.

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Associate Attending Physician
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

: Astellas Pharma, Bristol Myers Squibb, Eisai; 

: Astellas Pharma, AstraZeneca, Daiichi-Sankyo, Johnson & Johnson, Kura Oncology, Servier, Syndax Pharmaceuticals.

Associate Professor of Medicine, Hematology and Medical Oncology
Icahn School of Medicine at Mount Sinai
The Tisch Cancer Institute
New York, NY

: AbbVie, Agios, Disc Medicine, Incyte, Kura Oncology, MorphoSys, Protagonist Therapeutics, Silence Therapeutics.

Assistant Professor of Medicine, Hematology and Medical Oncology
Icahn School of Medicine at Mount Sinai
Adult Leukemia Program
The Tisch Cancer Institute
New York, NY

Oncology PER® Spectives™: Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations

, podcast host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, and Yan Leyfman, MD, a resident physician at Mount Sinai in New York, New York, discussed the origins and mission of 

, a global platform designed to combat health care misinformation and advance medical education. Conceived during the COVID-19 pandemic, 

 was created in response to widespread misinformation and a need for accessible, evidence-based information. Over the past 2 and a half years, the platform has expanded to reach over 100 countries, focusing on underserved regions and amplifying the voices of both established oncology leaders and early-career researchers.

The platform offers educational initiatives like Keynote Conference, a 1-hour session featuring expert presentations and interactive Q&A sessions; and Medical Spotlight, which highlights the professional journeys and research of global experts. 

 provides a real-world perspective on how oncologists incorporate trial data into clinical practice, addressing patient-specific considerations often missed in formal conferences. In this episode, Dr Park emphasized 

’s commitment to mentorship, providing trainees with opportunities to publish research, present at conferences, and secure residency placements, particularly those in resource-limited settings.

 to amplify its global reach, leveraging 

’s expansive platform to deliver concise, interactive, and accessible oncology education tailored to modern audiences. By emphasizing equity and inclusion, this initiative aims to address disparities in professional opportunities and foster a more diverse and innovative oncology community. In this discussion, Drs Park and Leyfman reaffirmed their commitment to advancing global medical education, mentoring future leaders, and bridging gaps in access to accurate health care information.

Drs Park and Leyfman discuss their commitment to advancing global medical education, mentoring future leaders, and bridging gaps in access to accurate health care information.

MedNews Week Advances Global Oncology Education and Combats Misinformation: With Chandler Park, MD; and Yan Leyfman, MD

that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays. 

Podcasts

All Podcast Series

How This Is Building Me

Two Onc Docs

Blood Club

FDA Approval Insights

Oncology Expert Insights

OncClub

Conference Perspectives

Women In Oncology

Rare Cancers

Disparities

Fellowship

Roundtable Discussions

CME Podcasts

Latest Conference Coverage